Associated Papers
Raw lacquer-associated familial chronic myelomonocytic leukemia with multi-hit TET2 mutations.
Zhang Y et al.
Frontiers in Oncology, 2025
Sequential tumor molecular profiling identifies likely germline variants.
Kraft IL et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2024
Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
Kim HY et al.
Annals of Laboratory Medicine, 2018
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W et al.
Blood, 2017
Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S et al.
British Journal of Haematology, 2016
27447873 (PubMed )
Supplement: supplement_1.doc
Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.
Shen W et al.
British Journal of Haematology, 2016
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
Yonal-Hindilerden I et al.
Journal of Blood Medicine, 2015
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G et al.
Plos One, 2014
24465546 (PubMed )
Supplement: pone.0085362.s001.pdf
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S et al.
Leukemia, 2013
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
Roche-Lestienne C et al.
Leukemia, 2011
Select a paper to view details